This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.
Merck &Co's – known as MSD outside the US and Canada – Prevymis (letermovir) demonstrated non-inferior efficacy and a more favourable safety profile compared to standard of care valganciclovir in a
The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate patients
Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved
Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....